GoodRx to Restate First-Half 2026 Financials Over Understated Revenue
Bitget2026/11/02 21:34- GoodRx Holdings on October 27, 2026, deemed first- and second-quarter financial statements unreliable due to understated Pharma Direct revenue.
- Revenue recognition errors violated ASC 606 requirements; amended Forms 10-Q will restate the affected periods.
- Expected adjustments would raise first-half total revenue by $29.77 million to $424.19 million.
- First-half net income is expected to increase by $14.85 million to $24.55 million.
- One or more material weaknesses in internal control over financial reporting are expected for both affected quarters.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Deutsche Bank made significant Q3 purchases of midstream AI application stocks: the three major cloud giants saw increased holdings, with Palantir (PLTR.US) and Salesforce (CRM.US) also favored.
Deutsche Bank has submitted its third quarter 13F holdings report for the period ending September 30, 2026.
Pendle Bridge integrates with BungeeExchange, supporting cross-chain transfers across 13 networks
Barclays significantly increased holdings in Tesla (TSLA.US) and Intel (INTC.US) in Q3, and bought Nasdaq ETF options for hedging
According to disclosures by the U.S. Securities and Exchange Commission (SEC), Barclays has submitted its third-quarter holdings report (13F) as of September 30, 2026.
Crypto prices
More
